secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001650664-26-000027
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

USPTO reaffirms Broad Institute's CRISPR/Cas9 patent priority; Editas' licensed patents upheld
--------------------------------------------------------------------------------

- PTAB issued third favorable decision for Broad over CVC on CRISPR/Cas9 editing in eukaryotic cells.
- CVC retains the right to appeal to the U.S. Court of Appeals for the Federal Circuit.
- Editas' exclusive license to the CRISPR/Cas9 patents at issue remains intact; other in-licensed patents not impacted.
- CEO Gilmore O'Neill cites confidence in IP, highlighting EDIT-401 with >90% mean LDL reduction in NHPs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066426000027/0001650664-26-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066426000027/edit-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001650664-26-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer